Trials / Conditions / Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma

Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma

11 registered clinical trials studyying Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma NCT05077527	AIDS Malignancy Consortium	Phase 1
Recruiting	Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymp NCT05672251	City of Hope Medical Center	Phase 2
Recruiting	Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patien NCT05821088	David Bond, MD	Phase 2
Withdrawn	Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Rec NCT05228249	Fred Hutchinson Cancer Center	Phase 1
Active Not Recruiting	Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin NCT05202782	Northwestern University	Phase 2
Active Not Recruiting	ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma NCT05025800	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Completed	Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma NCT04432506	M.D. Anderson Cancer Center	Phase 2
Unknown	Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated Wit NCT04870853	M.D. Anderson Cancer Center	—
Terminated	huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Ac NCT03103971	Fred Hutchinson Cancer Center	Phase 1
Terminated	JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma NCT02706405	Fred Hutchinson Cancer Center	Phase 1
Active Not Recruiting	R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphom NCT02628405	Academic and Community Cancer Research United	Phase 1 / Phase 2